KRAS and adenocarcinoma: In our investigated cohort of triple-negative NSCLCs (EGFR, KRAS, and BRAF mutation negative) the number of cases with either ROS1 or RET fusions were similar to that of ALK-positive cases, supporting the need of multiplexed gene fusion diagnostics in NSCLC and adenocarcinoma specifically.